Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
- HC Wainwright & Co. cut Can-Fite BioPharma Ltd. (NYSE: CANF) price target from $34 to $18. HC Wainwright & Co. analyst Vernon Bernardino maintained a Buy rating. Can-Fite BioPharma shares fell 6.8% to close at $1.92 on Monday. See how other analysts view this stock.
- Barclays slashed the price target for Arvinas, Inc. (NASDAQ: ARVN) from $39 to $26. Barclays analyst Peter Lawson maintained an Overweight rating. Arvinas shares closed at $14.55 on Monday. See how other analysts view this stock.
- Fermium Research lowered FMC Corporation (NYSE: FMC) price target from $85 to $62. Fermium Research analyst Frank Mitsch maintained a Hold ...